Initial Pharmacoeconomic Data Demonstrates Cost Benefits Of Altrazeal®

Apr 07, 2014, 08:00 ET from ULURU Inc.

ADDISON, Texas, April 7, 2014 /PRNewswire/ --ULURU Inc. (OTCQB: ULUR), is pleased to provide an update on the pharmacoeconomic analysis being conducted in Europe on Altrazeal®, the Company's innovative wound dressing. The purpose of this pharmacoeconomic analysis is to evaluate both the cost and healing benefits of Altrazeal® when compared to conventional dressings and advanced moist wound healing products.

The analysis is being conducted on defined-wound types and sizes, where there is a full thickness tissue loss. It is anticipated that the first results of this ongoing analysis will be completed prior to the end of the second quarter and its planned to have these results published in a peer reviewed international journal.

In medical literature many analyses have been reported and models established to determine the pharmacoeconomic benefits of wound care products. Additionally, there are many articles that detail the factors that influence the cost associated with wound care.

Hurd et. al. outline the cost and wound healing benefits derived in Niagara, Canada, through the use of a radical reorganization of wound management practices. By reducing the use of traditional wound care products from 75% in 2005 to 20% in 2007 the frequency of daily dressing changes were reduced from 48% to 15%, average healing times were reduced from 51.5 weeks to 20.9 weeks and costs per patient were reduced 75% to $3,560. In 2006 Wessig reported that 500 venous leg ulcer patients treated using conventional wound therapy experienced an average healing time of 280 days at a cost of $6,809. This report was based on original data from a German health insurance company.

In another article, Tennvall et. al. compared the total cost of healing venous leg ulcers in Sweden and the United Kingdom. The cost to heal a venous leg ulcer that was present greater than 6 months and larger than 10 cm2 was $3,540 in Sweden and $2,730 in the United Kingdom, of which 13-20% was the cost of the dressing. The average healing time of this patient population was 196 days. The major difference in total cost was the time taken to change the dressing and the difference in the average number of dressing changes which were 2.65 and 1.53 times per week in Sweden and the United Kingdom respectively.

The papers referenced above highlight the components that contribute to the escalation of wound treatment costs, namely, the use of inferior products, healing time, number of dressing changes and the time taken to change dressings. The extended wear time of Altrazeal®, simplicity of dressing changes and the potential for accelerating healing ideally positioned Altrazeal® to deliver important pharmacoeconomic benefits.

Commenting on the initial data, Helmut Kerschbaumer, Executive Director of Altrazeal AG, stated, "This initial data confirms the extensive global feedback that we have been receiving regarding reduced treatment costs. To-date, there have not been sufficient patients analyzed to comment on accelerated healing; however, initial indications are very encouraging. Given the reported global clinical experience and published clinical case series in numerous chronic wounds, these results are not surprising. This data will be used to support our global marketing activities."

Kerry P. Gray, President and CEO of ULURU Inc., commented, "This pharmacoeconomic analysis is a very important study to demonstrate the cost and clinical benefits of Altrazeal®. Studies clearly show that the cost of the dressing is not the principal component of the overall cost of wound care. With the extended wear time of Altrazeal®, relative to competitive products, it is logical that Altrazeal® will generate monthly treatment cost savings. The cost data generated, together with wound healing results should place us in a very favorable position when comparing Altrazeal® to both low cost alternatives and substantially higher priced therapies, including living-cell-based products, skin substitutes and other regenerative biomaterial approaches."

Altrazeal® is a scientifically engineered advanced wound dressing designed to incorporate the desired features and benefits of the ideal wound dressing. Altrazeal® competes in the advanced wound dressing market which, worldwide, is estimated to be $6.5 billion growing annually at 13%. Altrazeal® has demonstrated potential clinical and economic advantages in a number of chronic and acute wounds including diabetic foot ulcers, venous leg ulcers and geriatric wounds.

About ULURU Inc.:
ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex® Aggregate technology and OraDisc™ transmucosal delivery system.  For further information about ULURU Inc., please visit our website at  For further information about Altrazeal®, please visit

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended.  These statements are subject to numerous risks and uncertainties, including but not limited to the cost of Altrazeal treatment relative to competitors, benefits compared to other treatments both cost and clinical, normalized cost of treatment, extended wear time of Altrazeal®, the regulatory and reimbursement approval, the clinical and economic data supporting Altrazeal® and the risk factors detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2013, and other reports filed by us with the Securities and Exchange Commission.

Contact: Investor Relations

Contact: Company

Jim MacDonald                 

Kerry P. Gray

Torrey Hills Capital            

President & CEO

(858) 456-7300                  

Terry K. Wallberg 

Vice President & CFO

(214) 905-5145